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Background: Diabetic Peripheral Neuropathy is one of the most prevalent complications of diabetes mellitus. The
development and progression of such complications are responsible for much of the morbidity and mortality. The
purpose of this study was to evaluate the effectiveness of Semmes–Weinstein monofilament ten gram in 3, 4, eight
and ten points in the screening of diabetic peripheral neuropathy in patients with diabetes mellitus.
Methods: In a descriptive correlational design, 150 patients with diabetes mellitus were selected using convenience
sampling. All patients were evaluated for sensory neuropathy using ten gram Semmes-Weinstein Monofilaments
and questionnaire on neuropathy symptoms. In the next phase, nerve conduction velocity was examined. The most
common subjective symptoms were paresthesia of both feet, pain in feet, burning sensation in the extremities and
numbness in the extremities.
Results: The results showed that the sensitivity of Monofilament in three and four points were 35.9 to 53.8 present
and 38.5 to 51.3 percent respectively. Specificity of Monofilament the same points, were 73.9 to 84.7 and 73 to 87.4
percent respectively. Monofilament sensitivity at eight and ten points were 38.5 to 61.5 and 64.1 to 30.8 percent
respectively. Also, specificity of the same points were 77.5 to 95.5 and 64 to 89.2 percent respectively. It was
revealed that the difference sensitivity and specificity of Monofilament in three and four points with sensitivity and
specificity in eight and ten point is not statistically significant.
Conclusions: This study showed that Semmes-Weinstein monofilament can easily use as a simple and inexpensive
device for screening. Since increasing the number of points it was not significantly difference. Therefore, we
suggest that screening for diabetic peripheral neuropathy, especially in large populations to avoid wasting time
on Monofilament application, areas like three or four points eight and ten points could be used.
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Diabetes is the most common metabolic disease world-
wide. IDF and WHO reported increasing incidence all
around the world especially in developing countries [1].
Prevalence of diabetes mellitus (DM) in different parts
of Iran is between 7.5–7.9 percent. There are more than
3 million people diagnosed by DM, which unfortunately
increases three times every 15 years [2]. Diabetic neur-
opathy is one of the most common complications of DM* Correspondence: zarea_k@ajums.ac.ir
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stated.which can cause motor/sensory dysfunction in diabetic pa-
tient [3–5]. Peripheral sensory neuropathy is one of the
single strongest factors associated with the development
of foot ulcers, amputations, Charcot Arthropathy, and
other foot complications [6,7]. Diabetic neuropathy com-
plications include severe pain, loss of sensation, foot ulcer-
ation and amputation, burns, infection, cellulites, sleep
disorder, impaired daily functioning, mood disorders, gan-
grene, involvement of different systems such as cardiovas-
cular, gastrointestinal and reproductive systems [3,8].
These complications, especially ulcer and amputation,
affect the quality of patients’ life, which in turn leads to
repeated hospitalizations and increased health care coststd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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for the treatment of diabetic neuropathy and its compli-
cations in the U.S. Therefore, early prevention from the
complications of diabetic neuropathy is essential for the
recovery of these patients [10].
Several devices are used to track the performance of
protective sensation of the foot in diabetic patients.
Monofilaments, along with other methods such as evalu-
ation of pain sensation, sense of vibration, temperature
sense, and deep reflexes are considered the common
methods for the screening of DPN [11]. Nerve conduc-
tion test is an effective method for the diagnosis of DPN,
but this method is time consuming and expensive and
may not be suitable for patients’ diagnosis in outpatient
departments [12]. Many other methods as an alternative
method for the screening of DPN in patients with dia-
betes are available. Monofilaments including Semmes-
Weinstein Monofilament Testing (SWMT) are among
the safest and cheapest methods of DPN’s screening [6].
SWMT is so calibrated that if a force of 10 grams is ap-
plied to the extent that the monofilament is bent but the
patient does not feel it, then that point is considered as in-
sensate [13]. This is a simple test used to determine the
amount of DPN and predict the possibility of foot ulcer-
ation in patients with diabetes. In this test, certain points
of the feet are stimulated by putting monofilament on the
skin to determine the presence of sensation. This test has
high power of screening to determine the risk of foot
ulceration and reduces traumatic injuries [14,15].
Nurses, by using a monofilament as screening method,
also can provide the necessary training to prevent foot ulcer
and amputation (such as the use of appropriate footwear,
more precise control of blood sugar and fat, the monthly
check of the incidence of neuropathy and increased blood
sugar, and the use of walker) to those at risk of neuropathy
[16,17]. In other words, teaching patients about how to use
monofilament at home not only prevents from the compli-
cations, but also is a high motivational factor for patients in
order to better control their blood sugar levels [18-20]. It
also reduces psychological problems followed by an early
diagnosis of DPN in susceptible patients alongside increas-
ing in patients’ quality of life [15,21].
Clinical care guidelines have recommended that annual
screening for peripheral neuropathy occur in all patients
with diabetes, as part of the routine evaluation of patients
in terms of complications [22]. The sensitivity of the
SWMT used by Miranda-Palma to track the reduction of
sensation in three points of the sole was reported to be
between 65% to 86% [23]. Nather et al. (2008) compared
the incidence of neuropathy diagnosed by three devices:
pin-prick, SWMT, and neurometer. It was shown that
the rate of sensory neuropathy diagnosed by the pin-
prick and neurometer tests was significantly higher than
that of SWMT [24]. The SWMT is so calibrated that aforce of 10 grams is applied to the extent that the
monofilament is bent, but if the patient does not feel it,
that point is considered insensate [15].
In the international study this test was conducted on
10 and 15 points, and the results have been different.
Since in the most studies, a 10 g monofilament has been
used often for screening, and no study still has been
conducted for comparing 10 g monofilament in different
points carefully, this study was designed with the following
objectives: The first aim of our study was to answer the
question that whether increasing the number of points to
use in screening monofilament neuropathy can be accom-
panied with high sensitivity? The second objective was to
compare the sensitivity and specificity of monofilament
with the Modified neuropathy disability score.
Methods
A quasi-experimental design was used to conduct this
study. This research was conducted from 2010 to 2011
with 150 patients suffering from type II, DM referred to a
Diabetic Clinic affiliated to a teaching hospital in Ahvaz,
Iran.
Using a statistical sampling formula with α = 0.05, β =
0.2, p1 = 0.86, p2 = 0.96 adopted from other studies [23]
the number of samples was 150 people
n ¼ z1−α=2 þ z1−β
 2
p1 1−p1ð Þ þ p2 1−p2ð Þ½ 
p1−p2ð Þ2
¼ 148≅150
The patients with type II, DM with the following cri-
teria entered the study: (a) having no diabetic foot ulcer;
(b) having a stable clinical condition; (c) having no psy-
chological problem, (d) having no history of brain stroke,
and neuropathy due to other reasons such as hereditary-
acquired neuropathy or the Guillain-Barre Syndrome; (e)
having no callous or any other complications in feet; (f )
being able to communicate verbally; and (g) Being inter-
ested in participating in this study.
Ethical considerations
After the approval of the study at the Ethics Committee
of Jundishapur Medical Sciences University (No.3040),
Ahvaz, Iran, informed consent was taken from the patients
for participating in the study. Also, the patients received
enough information about the safety of this method and
their freedom for entering into or exiting the study.
Instrument
Questionnaire on neuropathy symptoms
In order to examine the mental symptoms of neuropathy,
The following 13 questions were Prepared: (1) pain in
hands; (2) pain in feet; (3) numbness at terminal points;
(4) paraesthesia of both feet; (5) burning sensation in the
extremities; (6) cold sensation in the extremities; (7)
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fainting; (11) dizziness; (12) problems in urinating; (13)
ulcers at feet. These symptoms were classified to the
following 4 categories: asymptomatic, mild, moderate,
and sever. The patients were accordingly divided to two
groups of asymptomatic and symptomatic (the total of
mild, moderate, and sever) [25].
Semmes-Weinstein Monofilament Testing (SWMT)
In this study, we used Semmes-Weinstein monofilament
(North Coast Medical, Inc., San Jose, CA) with a repro-
ducible buckling stress 10 grams. Monofilament testing
was performed on both feet of the patients by the first
author, who had received the necessary training on the
use of monofilament. The test at 3, 4, 8, and 10 points
of the feet were evaluated. Three points in each foot
were the great toe, the plantar aspect of the first meta-
tarsal head; and the plantar aspect of the fifth metatarsal
head. Four points in each foot, including: the plantar
surface of hallux, and the first, third, and fifth metatarsal
heads. Eight points in each foot, including: the dorsal as-
pect of the first, second, third, fourth, and fifth digits;
the dorsal aspect of medial, central, and lateral aspect of
mid foot and ten points in each foot, including: nine
plantar sites (distal great toe, third toe, and fifth toe;
first, third, and fifth metatarsal heads; medial foot, lateral
foot, and heal) and one dorsal site.
Procedure
The monofilament was accidentally placed on palm of
the patient’s hand while his/her eyes were closed and
each patient was asked the following questions:
 Do you feel the monofilament on the palm?
 Which part of your hand is in contact with the
monofilament?
After it was ensured that the patient understood how to
cooperate and how to answer questions, the monofila-
ments on the bottom of both feet of the patient were
placed, while the patient’s eyes were closed. The monofila-
ment was placed on the portion of the patient’s skin,
which had no callus, and was pressed as far as the mono-
filament could be bent. The patient was asked whether he/
she felt something on the sole and on which foot he/she
felt the monofilament. In each point, the test was repeated
for three times. If the patient answered incorrectly two or
more times in that point, it was recorded as a positive
symptom of neuropathy [25]. The duration of conducting
the test on both feet was for 5 to 10 minutes.
Modified neuropathy disability score (NDS)
This score (maximum 10) is derived from abnormalities
of pain sensation using a Pin-Prick, vibration sensationusing a 128 Hz tuning fork, dorsal temperature sensa-
tion using warm and cold rods and Achilles tendon re-
flexes using a tendon hammer [26,27].
Examination of pain sensation
Pin prick test was used for this purpose. First, the pa-
tient was asked whether he/she felt needles sensation or
numbness in the hands or feet. None of the patients ex-
perienced sensory impairment in their hands. Then, the
test was performed with the pin using a standard pro-
cedure for all patients by the second author. In this pro-
cedure, while the patient’s eyes were opened, the pin
prick was vertically pressed on the skin behind the fore-
arm of the patient until the patient began to express
pain. The same test was then repeated with the same
amount of pressure on the dorsal surface of the hand to
cause pain. Then parts of the toes, forefoot, midfoot,
hind foot were tested with the same pin and with the
same amount of pressure and the patients were asked
whether the pain in the feet is more (hyperesthesia)/less
(hypoesthesia) than or similar to the pain in the hands.
Then in the next step, while the patient’s eyes were
closed, the test was performed with the above procedure
and the patient was asked to raise his/her right hand
when he felt pain. The locations that had sensory im-
pairment (either as hyperesthesia or as hypoesthesia)
were noted as positive sites. There are two types of sen-
sory disturbances indicating the presence of neuropathy.
For each patient, a pin with the same type was used [24].
Testing of the temperature sense
Hot and cold water pipes were used on the patient’s thumb.
Temperature of the cold water pipe was not less than 25°C,
and temperature of the hot water pipe was not more than
45°C, because otherwise it would cause pain [24].
Examination of the sense of vibration
A 128 Hz tuning fork was used. First, the patient was
taught, by placing the vibrating tuning fork on the fore-
head or sternum, that understanding the sense of shak-
ing or vibration is intended, not just the tuning fork’s
contact with the body. After we realized that the patient
understood what we meant, we vibrated the tuning fork
with the stroke of the palm of the hand, and it was put
on the bony prominence on the back of the thumb. The
patient was asked to report the perception of both the
start of the vibration sensation and cessation of vibration
on dampening [24].
Achilles reflex testing
Achilles reflex was evaluated on the condition that the
patient was bent on the stomach and his/her knees were
bent at 90 degrees. We stroked Achilles tendon, and saw
the patient’s response. Normal response is as a plantar
Table 1 Demographics variables in the patients
Demographic variables Mean ± SD or n (%)
Age 8.95 ± 55.71
Sex: Male 47(31.3)
Female 103(68.7)
Duration of disease 6.1 ±7.7
FBS 72.66 ±169.92
HbA1c 3.96 ± 8.26
CHLO 44.10 ± 182.31
TG 54.87 ± 127.49
HDL 12.24 ± 47.21
LDL 34.09 ± 100.21
BMI 4.85 ± 27.45
Weight 8.99 ± 55.35
Table 2 Sensitivity and specificity of the 10 g
monofilament according to the number of insensate sites
Testing site Sensitivity Specificity
Monofilament ≥1/8* 51.3 73
Monofilament ≥ 2/8† 46.2 74.8
Monofilament ≥4/8‡ 38.5 87.4
*Minimum of 8 point 1 point reported by patients as a numbness site.
†Minimum of 8 point 2 point reported by patients as numbness site.
‡Minimum of 8 point 4 point reported by patients as numbness site.
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creased reflexes or absent reflexes [24].
For one foot, each sensory test scored zero for normal
sensation or one for abnormal sensation: ankle reflex
scored zero if present, one if present with reinforcement
or two if absent. Pain and temperature sensation were
assessed on the dorsal surface of the great toe after the
stimuli were demonstrated at a proximal, normal site.
Vibration perception was assessed using the 128 Hz tun-
ing fork over the apex of the hallux. The Achilles tendon
reflex was assessed with the patient supine on a couch.
The maximum score for the two feet is 10, with a score
of ≥6 indicating moderate to severe neuropathy [26,28].
Diagnostic criterion for DPN
In order to diagnose DNP, the nerve conduction velocity
(standard test) was also measured. The technician for
measuring the nerve conduction velocity was quite blind
about the clinical Testing. To identify the sensitivity and
specificity of the SWMT, the results of the monofilament
Testing were compared with the nerve conduction vel-
ocity as the gold test. The neural conduction tests are
recommended by other studies as the gold test for asses-
sing and validating screening tests for diabetic neur-
opathy [29–31].
Data analysis
The data analysis was performed using the SPSS software
Ver.16. The Sensitivity and specificity of the SWMT were
measured. The data were presented as means and stand-
ard deviations, and percentiles.
Results
From among the 150 patients participating in the study,
there were 47 males (31.3%) and 103 females (68.7%).
The average age of the patients was 55.71 ± 8.95 years and
the mean of disease duration was 7.7 ± 6.1 years. The mean
fasting blood glucose, the mean HbA1c, the mean choles-
terol, the mean triglycerides, the mean HDL Blood, the
mean LDL Blood level, the mean BMI and the mean weight
in patients were 169.92 ± 72.66, 8.26 ± 3.96, 182.31 ± 44.10,
127.49 ± 54.87, 47.21 ± 12.24, 100.21 ± 34.09, 27.45 ± 4.85,
and 55.35 ± 8.99, respectively. All patients were under treat-
ment with oral medication. Drug regimen for most patients
was glibenclamide and metformin (Table 1).
The results showed that the majority of patients (75.
34%) have had HbA1c levels greater than 7%. It is
shown that these patients have had a poor control over
their diabetes. Among the clinical manifestations of
neuropathy, paresthesia (72%), pain at feet (71.3%),
feeling of pins and needles at feet tips (71.3%), numb-
ness at terminals (63.3%), pain in hands (61.3%), and
coldness at feet (50.7%) had the highest prevalence
among the patients. Totally, through the examinationof symptoms, 93 patients were healthy and without
neuropathy and 57 individuals (38%) had neuropathy.
Testing with the 10 g monofilament was assessed ac-
cording to different cut-off points for positivity (Table 2).
(a) From 6 points, at least one point as a local insensate
has been reported by the patient, (b) From 6 points, at
least two points as a local insensate have been reported
by the patient and (c) From 6 points, at least 3 points as
a local insensate have been reported by the patients.
The procedure for 4 points, 8 points, and 10 points
were used in each plantar foot. So that a minimum one
points out of 8 points, at least two points out of 8
points, and 4 points out of 8 points at numb have been
reported. At least, one point of 16 points, two points out
of 16 points, eight points out of 16 points at numb have
been reported. At least, one point out of 20 points, two
points out of 20 points, 10 points out of 20 points at
numb have been reported (Tables 3, 4 and 5).
We also compared the results of monofilament with
the improved sensitivity and specificity of the improved
neuropathy criterion and the tuning fork tests (Table 6).
Patients who acquired scores greater than, or equal to, 6
of the improved neuropathy criterion, were defined as
patients with neuropathy symptoms [15,30]. The sensi-
tivity and specificity of these two criteria were obtained
91% and 94.9% respectively.
Table 3 Sensitivity and specificity of the 10 g
monofilament according to the number of insensate sites
Testing site Sensitivity Specificity
Monofilament ≥1/6* 53.8 73.9
Monofilament ≥ 2/6† 43.6 79.3
Monofilament ≥3/6‡ 35.9 84.7
*Minimum of 6 point 1 point reported by patients as a numbness site.
†Minimum of 6 point 2 point reported by patients as numbness site.
‡Minimum of 6 point 3 point reported by patients as numbness site.
Table 5 Sensitivity and specificity of the 10 g
monofilament according to the number of insensate sites
in 16points according to insensate sites
Testing site Sensitivity Specificity
Monofilament ≥1/16* 61.5 77.5
Monofilament ≥ 2/16† 59 79.3
Monofilament ≥8/16‡ 38.5 95.5
*Minimum of 16 point 1 point reported by patients as a numbness site.
†Minimum of 16 point 2 point reported by patients as numbness site.
‡Minimum of 16 point 8 point reported by patients as numbness site.
Table 6 Sensitivity and specificity according to
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that of the 150 patients with neuropathy participating in
the study, 138 patients have acquired scores equal to or
greater than 6, and it shows that according to this criter-
ion, 92% of our patients had been moderate to severe
symptoms of neuropathy.
Moreover, the tuning fork testing that is part of NDS
criterion was evaluated separately. Thus, the lack of the
tuning fork vibration sense on one of the big toes was
used as a positive point. Sensitivity and specificity of
tuning fork was alone at these points 84.6% and 43.2%
respectively. The sensitivity and specificity of both tests
were greater than monofilament.
Discussion
The use of this test in our study showed that when fac-
tors such as cost and ease of use are concerned, then
10-g Semmes-Weinstein monofilament are effective for
detection and screening of the foot protective sense re-
duction about the diabetic foot. In this study, we applied
Semmes-Weinstein monofilament in 3, 4, 8 and 10
points per the sole of the foot. If we look at the results
of monofilament in these points, we see that the sensi-
tivity of monofilaments was in the range of 30.8%–
64.1%. This relatively low sensitivity implies that these
abnormal areas and the numb points only can be diag-
nosed in very severe neuropathies. Also, according to
the obtained results, we see that sensitivity and specificity
of monofilament in 3points and 4points have not statisti-
cally significant difference with sensitivity and specificity
in the 8 points and 10 points. In other words, with in-
creasing the number of studied points, the monofilament
sensitivity has not been increased. Therefore, we recom-
mend that physicians or nurses use from fewer points likeTable 4 Sensitivity and specificity of the 10 g
monofilament according to the number of insensate sites
Testing site Sensitivity Specificity
Monofilament ≥1/20* 64.1 64
Monofilament ≥ 2/20† 61.5 64
Monofilament ≥10/20‡ 30.8 89.2
*Minimum of 20 point 1 point reported by patients as a numbness site.
†Minimum of 20 point 2 point reported by patients as numbness site.
‡Minimum of 20 point 10 point reported by patients as numbness site.3 points and 4points to screen the patients with diabetes,
and do not spend their time to use monofilament in more
points.
In this study, the sensitivity of monofilament in 3 points
and specificity of this test were (38.5%–51.3%) and (73%–
87.4%) respectively. Kamei in his study, reported sensitivity
and sensitivity of 10-g Semmes-Weinstein monofilament in
3 points, 5%–22.5% and 88.1%–97.6% respectively [25] that
compared with our study, the sensitivity of monofilament
was less, but its specificity was higher; this can be on a
number of samples, sample type and other characteristics
of patients and limitations of each study.
Moreover, in this study, the sensitivity and specificity of
monofilament in the 4 points were 38.5%–51.3% and 73%–
87.4% respectively. Miranda-Palma et al., reported the
range of sensitivity and specificity of Semmes-Weinstein
10 g monofilament at four sites, from 65% to 86%, and
58% to 71%, respectively [23]. In this study, the sensitivity
and specificity of monofilament in 8 points were 38.5–61.5
and 77.5%–95.5 respectively. Also the sensitivity and speci-
ficity of monofilament at 10 points were 30.8%–64.1% and
64%–89.2% respectively. Mason and colleagues reported
sensitivity and specificity of monofilament at 10 points,
respectively 92.1%, and 100% [30].
Although the use of monofilament has been started
since 1995, but the number of points that must be consid-
ered is still under study. In our study, the prevalence of
diabetic neuropathy on the basis of a positive test 10–g
Semmes-Weinstein monofilament is the 9.33%–24% [32].
This finding is different from other studies, including in
Forouzandeh’s study, prevalence of diabetic neuropathymethodologies used to assess insensitivity
Test Sensitivity Specificity
Monofilament ≥1/6 53.8 73.9
Monofilament ≥1/8 51.3 73
Monofilament ≥1/16 61.5 77.5
Monofilament ≥1/20 64.1 64
NDS 94.9 91
128 Hz tuning forka 84.6 43.2
a≥1 of the two sites tested was considered positive.
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which this case could be due to the number of samples in-
volved, the type of sampling, the number of points to be
considered [29].
Nevertheless, the aim of our study was the use of mono-
filament as a screening measure of peripheral neuropathy,
while they used monofilament to track down and detect
the numb foot to prevent lower limb amputation. Further-
more, their study differs from ours, because they com-
pared the sensitivity and specificity of 10-g monofilament
with vibration test as the gold test while we used nerve
conduction tests (NCV) as the gold test.
The above examples demonstrate that subtle changes in
abnormal response to monofilament can cause differences
in the prevalence of numbness in feet between 3.4%–29%.
On the other hand, for simple things like monofilament,
small changes in the force imposed to monofilament can
lead to misleading results and unusual effects. For this rea-
son, there is a disagreement for its use in distinctive coun-
tries which it can lead to an ambiguity in epidemiological
researches and to estimate the need in the health care
[3,15,31,33]. More research is needed to investigate the en-
vironmental condition’s effects such as temperature, and
moisture that can affect the force required to bend the
monofilament (which is usually 10 grams) [34].
In this study, we used a questionnaire for subjective
signs in order to investigate the neuropathy. Results of
Testing of the signs showed that 93 persons were
healthy and without signs of neuropathy, and 57 persons
(38%) were with neuropathy. Pain and tingling sensation
had the most prevalence among the clinical signs of
paresthesia. In 78.7% of the patients, knee reflexes di-
minished or disappeared; and in 64% of patients, vibra-
tion sense was impaired. Our content can be also
confirmed by Kamei’ study, where 51.2% of patients suf-
fered from the pain, numbness, and paresthesia in both
legs. In 56.1% of the patients, knee reflexes were reduced
or eliminated; and vibration test in 36.6% of the patients
was impaired. In this same study, the majority of pa-
tients had muscle cramps, numbness in the extremities,
and the moderate to severe pain [25].
Monofilament test cannot be favorably compared with
other methods. The results of a comparison between
monofilament tests with standard NDS showed that the
sensitivity and specificity of NDS criterion are high.
While the results of Miranda Palma’s study showed that
the sensitivity of monofilament is higher than NDS, but
its specificity was lower than in the standard [24].
Therefore, the different results obtained certainly cannot
say which of these methods are superior to both It must
be considered that if these methods can be used to-
gether, then more accurate results can be achieved.
Although other studies have used the NDS as the accur-
ate and useful method for investigating the environmentalsense, but reasons to use the monofilament method are to
be easy, to be available, and to be cheap [3,9,24,32]. It
should be noted that the time required for this test is
pretty short. However, NDS require more time and equip-
ment and skills. In other words, employing monofilament
by a doctor or nurse or even the patient is a lot easier. So
that using monofilament, and screening, the patients can
prevent the undesirable complications such as foot ulcers
and amputation. With the help of this test, we can identify
these individuals susceptible to, and at risk, and present
the necessary instructions to them for preventing the foot
ulcers and amputation such as the use of proper footwear,
more accurate control of blood sugar and blood fat. Blood
sugar checked monthly incidence of neuropathy and in-
creased use of Walker and others.
Associated with glycemic control, HbA1c and fasting
blood-glucose levels in this study showed that most pa-
tients have poor blood-glucose control and were not
able to maintain normal blood sugar range themselves.
Therefore, this study can provide evidence for physi-
cians, nurses, and healthcare policy makers, so they can
make changes in the current health system, including to
provide the necessary and sufficient training to patients,
and to follow the screening of the patients more ser-
iously in both hospital wards and outpatient clinics.
Moreover, we investigated screening for diabetic per-
ipheral neuropathy in our study, and concluded that
none of the patients involved in the study were not stud-
ied in terms of diabetic peripheral neuropathy and its
complications. In other words, the present study is the
first study to screen the patient with diabetes. These
findings show that the screening of diabetic peripheral
neuropathy is poor in Ahvaz that should be improved.
Conclusions
Overall, by increasing the number of points for neur-
opathy screening, the sensitivity monofilament did not in-
crease. In other words, the sensitivity of monofilament in
3 and 4 points is almost similar to it in 8 and 10 points.
The use of monofilament solely or in combination
with NDS or other reflex tests for neuropathy screening
method is an easy and accessible method; and by early
detection, it can prevent complications that include leg
ulcers and amputation in patients with diabetes. The
Testing also seems to be important in this context, and
it cannot be released from it along with taking a profile.
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